284 related articles for article (PubMed ID: 14638501)
21. Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C.
Mello C; Aguayo E; Rodriguez M; Lee G; Jordan R; Cihlar T; Birkus G
Antimicrob Agents Chemother; 2014; 58(3):1546-55. PubMed ID: 24366736
[TBL] [Abstract][Full Text] [Related]
22. Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial.
Sperber SJ; Hendley JO; Hayden FG; Riker DK; Sorrentino JV; Gwaltney JM
Ann Intern Med; 1992 Jul; 117(1):37-41. PubMed ID: 1317694
[TBL] [Abstract][Full Text] [Related]
23. Oral prednisone therapy in experimental rhinovirus infections.
Gustafson LM; Proud D; Hendley JO; Hayden FG; Gwaltney JM
J Allergy Clin Immunol; 1996 Apr; 97(4):1009-14. PubMed ID: 8655877
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds.
Sperber SJ; Sorrentino JV; Riker DK; Hayden FG
Bull N Y Acad Med; 1989 Jan; 65(1):145-60. PubMed ID: 2557947
[TBL] [Abstract][Full Text] [Related]
25. Effect of clarithromycin on experimental rhinovirus-16 colds: a randomized, double-blind, controlled trial.
Abisheganaden JA; Avila PC; Kishiyama JL; Liu J; Yagi S; Schnurr D; Boushey HA
Am J Med; 2000 Apr; 108(6):453-9. PubMed ID: 10781777
[TBL] [Abstract][Full Text] [Related]
26. Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data.
Hemilä H; Chalker E
Pharmacol Res Perspect; 2021 Aug; 9(4):e00810. PubMed ID: 34128358
[TBL] [Abstract][Full Text] [Related]
27. Echinacea purpurea for prevention of experimental rhinovirus colds.
Sperber SJ; Shah LP; Gilbert RD; Ritchey TW; Monto AS
Clin Infect Dis; 2004 May; 38(10):1367-71. PubMed ID: 15156472
[TBL] [Abstract][Full Text] [Related]
28. Intranasal lymphoblastoid interferon ("Wellferon") prophylaxis against rhinovirus and influenza virus in volunteers.
Phillpotts RJ; Higgins PG; Willman JS; Tyrrell DA; Freestone DS; Shepherd WM
J Interferon Res; 1984; 4(4):535-41. PubMed ID: 6094684
[TBL] [Abstract][Full Text] [Related]
29. Randomized controlled trial of clemastine fumarate for treatment of experimental rhinovirus colds.
Gwaltney JM; Park J; Paul RA; Edelman DA; O'Connor RR; Turner RB
Clin Infect Dis; 1996 Apr; 22(4):656-62. PubMed ID: 8729205
[TBL] [Abstract][Full Text] [Related]
30. Combined antiviral-antimediator treatment for the common cold.
Gwaltney JM; Winther B; Patrie JT; Hendley JO
J Infect Dis; 2002 Jul; 186(2):147-54. PubMed ID: 12134249
[TBL] [Abstract][Full Text] [Related]
31. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections.
Mukherjee PK; Esper F; Buchheit K; Arters K; Adkins I; Ghannoum MA; Salata RA
BMC Infect Dis; 2017 Jan; 17(1):74. PubMed ID: 28088167
[TBL] [Abstract][Full Text] [Related]
32. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection.
Farr BM; Gwaltney JM; Hendley JO; Hayden FG; Naclerio RM; McBride T; Doyle WJ; Sorrentino JV; Riker DK; Proud D
J Infect Dis; 1990 Nov; 162(5):1173-7. PubMed ID: 2172395
[TBL] [Abstract][Full Text] [Related]
33. Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness.
Hayden FG; Gwaltney JM
J Infect Dis; 1983 Sep; 148(3):543-50. PubMed ID: 6311914
[TBL] [Abstract][Full Text] [Related]
34. Ineffectiveness of recombinant interferon-beta serine nasal drops for prophylaxis of natural colds.
Sperber SJ; Levine PA; Sorrentino JV; Riker DK; Hayden FG
J Infect Dis; 1989 Oct; 160(4):700-5. PubMed ID: 2551976
[TBL] [Abstract][Full Text] [Related]
35. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
Binford SL; Weady PT; Maldonado F; Brothers MA; Matthews DA; Patick AK
Antimicrob Agents Chemother; 2007 Dec; 51(12):4366-73. PubMed ID: 17908951
[TBL] [Abstract][Full Text] [Related]
36. [Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
Geppe NA; Kondiurina EG; Galustian AN; Pak TE; Bal'tserovich NB; Zhiglinskaia OV; Kamaev AV; Lazareva SG; Laléko SL; Mel'nikova IM; Perminova OA; Sabitov AU
Antibiot Khimioter; 2014; 59(5-6):6-14. PubMed ID: 25552038
[TBL] [Abstract][Full Text] [Related]
37. Intranasally administered atropine methonitrate treatment of experimental rhinovirus colds.
Gaffey MJ; Gwaltney JM; Dressler WE; Sorrentino JV; Hayden FG
Am Rev Respir Dis; 1987 Jan; 135(1):241-4. PubMed ID: 3800150
[TBL] [Abstract][Full Text] [Related]
38. Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds.
Farr BM; Conner EM; Betts RF; Oleske J; Minnefor A; Gwaltney JM
Antimicrob Agents Chemother; 1987 Aug; 31(8):1183-7. PubMed ID: 2820298
[TBL] [Abstract][Full Text] [Related]
39. Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults.
Sperber SJ; Levine PA; Innes DJ; Mills SE; Hayden FG
J Infect Dis; 1988 Jul; 158(1):166-75. PubMed ID: 2839579
[TBL] [Abstract][Full Text] [Related]
40. Combined antiviral and antimediator treatment of rhinovirus colds.
Gwaltney JM
J Infect Dis; 1992 Oct; 166(4):776-82. PubMed ID: 1326582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
